(Reuters) - Lilly posted strong revenue gains from Cymbalta and Zyprexa for schizophrenia, which rose 67 percent and 9 percent, respectively, and helped the company beat revenue expectations by about $250 million.
"Together these two products accounted for almost two thirds of the revenue beat," JPMorgan analyst Roberto Cuca wrote in a research note. "This should boost sentiment among those investors who had been concerned about the health of Lilly's franchise."
Read more at Reuters.com Market News
"Together these two products accounted for almost two thirds of the revenue beat," JPMorgan analyst Roberto Cuca wrote in a research note. "This should boost sentiment among those investors who had been concerned about the health of Lilly's franchise."
Read more at Reuters.com Market News
No comments:
Post a Comment